 14. Hypersensitivityinfusion reaction to monoclonal antibodies, other therapeutic proteins, or allergy to any componentexcipient of FS102 finished drug product arginine, glycine, phosphoric acid, or polysorbate 80 and the reaction could not be controlled or prevented on subsequent infusion with standard therapies such as anti-histamines, 5-HT3 antagonists, or corticosteroids. 